Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Mario, Rabe, Klaus F., Corren, Jonathan, Pavord, Ian D., Katelaris, Constance H., Tohda, Yuji, Zhang, Bingzhi, Rice, Megan S., Maroni, Jaman, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H., Teper, Ariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://www.ncbi.nlm.nih.gov/pubmed/32010719
http://dx.doi.org/10.1183/23120541.00204-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://www.ncbi.nlm.nih.gov/pubmed/32010719
http://dx.doi.org/10.1183/23120541.00204-2019

Ejemplares similares